These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

145 related items for PubMed ID: 19501260

  • 1. Rapamycin enhances aplaviroc anti-HIV activity: implications for the clinical development of novel CCR5 antagonists.
    Latinovic O, Heredia A, Gallo RC, Reitz M, Le N, Redfield RR.
    Antiviral Res; 2009 Jul; 83(1):86-9. PubMed ID: 19501260
    [Abstract] [Full Text] [Related]

  • 2. Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro.
    Maeda K, Nakata H, Koh Y, Miyakawa T, Ogata H, Takaoka Y, Shibayama S, Sagawa K, Fukushima D, Moravek J, Koyanagi Y, Mitsuya H.
    J Virol; 2004 Aug; 78(16):8654-62. PubMed ID: 15280474
    [Abstract] [Full Text] [Related]

  • 3. Reduction of CCR5 with low-dose rapamycin enhances the antiviral activity of vicriviroc against both sensitive and drug-resistant HIV-1.
    Heredia A, Latinovic O, Gallo RC, Melikyan G, Reitz M, Le N, Redfield RR.
    Proc Natl Acad Sci U S A; 2008 Dec 23; 105(51):20476-81. PubMed ID: 19075241
    [Abstract] [Full Text] [Related]

  • 4. Rapamycin causes down-regulation of CCR5 and accumulation of anti-HIV beta-chemokines: an approach to suppress R5 strains of HIV-1.
    Heredia A, Amoroso A, Davis C, Le N, Reardon E, Dominique JK, Klingebiel E, Gallo RC, Redfield RR.
    Proc Natl Acad Sci U S A; 2003 Sep 02; 100(18):10411-6. PubMed ID: 12915736
    [Abstract] [Full Text] [Related]

  • 5. Antiviral activity and safety of aplaviroc, a CCR5 antagonist, in combination with lopinavir/ritonavir in HIV-infected, therapy-naïve patients: results of the EPIC study (CCR100136).
    Yeni P, Lamarca A, Berger D, Cimoch P, Lazzarin A, Salvato P, Smaill FM, Teofilo E, Madison SJ, Nichols WG, Adkison KK, Bonny T, Millard J, McCarty D, EPIC (CCR100136) study team.
    HIV Med; 2009 Feb 02; 10(2):116-24. PubMed ID: 19200175
    [Abstract] [Full Text] [Related]

  • 6. Chemokine (C-C motif) receptor 5-using envelopes predominate in dual/mixed-tropic HIV from the plasma of drug-naive individuals.
    Irlbeck DM, Amrine-Madsen H, Kitrinos KM, Labranche CC, Demarest JF.
    AIDS; 2008 Jul 31; 22(12):1425-31. PubMed ID: 18614865
    [Abstract] [Full Text] [Related]

  • 7. Potent synergistic anti-human immunodeficiency virus (HIV) effects using combinations of the CCR5 inhibitor aplaviroc with other anti-HIV drugs.
    Nakata H, Steinberg SM, Koh Y, Maeda K, Takaoka Y, Tamamura H, Fujii N, Mitsuya H.
    Antimicrob Agents Chemother; 2008 Jun 31; 52(6):2111-9. PubMed ID: 18378711
    [Abstract] [Full Text] [Related]

  • 8. Identification and characterization of INCB9471, an allosteric noncompetitive small-molecule antagonist of C-C chemokine receptor 5 with potent inhibitory activity against monocyte migration and HIV-1 infection.
    Shin N, Solomon K, Zhou N, Wang KH, Garlapati V, Thomas B, Li Y, Covington M, Baribaud F, Erickson-Viitanen S, Czerniak P, Contel N, Liu P, Burn T, Hollis G, Yeleswaram S, Vaddi K, Xue CB, Metcalf B, Friedman S, Scherle P, Newton R.
    J Pharmacol Exp Ther; 2011 Jul 31; 338(1):228-39. PubMed ID: 21459966
    [Abstract] [Full Text] [Related]

  • 9. HIV-1 resistance to CCR5 antagonists associated with highly efficient use of CCR5 and altered tropism on primary CD4+ T cells.
    Pfaff JM, Wilen CB, Harrison JE, Demarest JF, Lee B, Doms RW, Tilton JC.
    J Virol; 2010 Jul 31; 84(13):6505-14. PubMed ID: 20410277
    [Abstract] [Full Text] [Related]

  • 10. Recent advances of CCR5 antagonists.
    Baba M.
    Curr Opin HIV AIDS; 2006 Sep 31; 1(5):367-72. PubMed ID: 19372835
    [Abstract] [Full Text] [Related]

  • 11. In vitro and clinical investigation of the relationship between CCR5 receptor occupancy and anti-HIV activity of Aplaviroc.
    Demarest JF, Sparks SS, Schell K, Shibayama S, McDanal CB, Fang L, Adkison KK, Shachoy-Clark A, Piscitelli SC.
    J Clin Pharmacol; 2008 Oct 31; 48(10):1179-88. PubMed ID: 18676693
    [Abstract] [Full Text] [Related]

  • 12. HIV type 1 from a patient with baseline resistance to CCR5 antagonists uses drug-bound receptor for entry.
    Tilton JC, Amrine-Madsen H, Miamidian JL, Kitrinos KM, Pfaff J, Demarest JF, Ray N, Jeffrey JL, Labranche CC, Doms RW.
    AIDS Res Hum Retroviruses; 2010 Jan 31; 26(1):13-24. PubMed ID: 20055594
    [Abstract] [Full Text] [Related]

  • 13. Rapamycin reduces CCR5 density levels on CD4 T cells, and this effect results in potentiation of enfuvirtide (T-20) against R5 strains of human immunodeficiency virus type 1 in vitro.
    Heredia A, Gilliam B, Latinovic O, Le N, Bamba D, Devico A, Melikyan GB, Gallo RC, Redfield RR.
    Antimicrob Agents Chemother; 2007 Jul 31; 51(7):2489-96. PubMed ID: 17485501
    [Abstract] [Full Text] [Related]

  • 14. Maraviroc: new drug. Multiple antiretroviral treatment failure: too soon to reach conclusions.
    Prescrire Int; 2008 Jun 31; 17(95):98-101. PubMed ID: 18623908
    [Abstract] [Full Text] [Related]

  • 15. Potent anti-R5 human immunodeficiency virus type 1 effects of a CCR5 antagonist, AK602/ONO4128/GW873140, in a novel human peripheral blood mononuclear cell nonobese diabetic-SCID, interleukin-2 receptor gamma-chain-knocked-out AIDS mouse model.
    Nakata H, Maeda K, Miyakawa T, Shibayama S, Matsuo M, Takaoka Y, Ito M, Koyanagi Y, Mitsuya H.
    J Virol; 2005 Feb 31; 79(4):2087-96. PubMed ID: 15681411
    [Abstract] [Full Text] [Related]

  • 16. CCR5 antagonists: comparison of efficacy, side effects, pharmacokinetics and interactions--review of the literature.
    Emmelkamp JM, Rockstroh JK.
    Eur J Med Res; 2007 Oct 15; 12(9):409-17. PubMed ID: 17933722
    [Abstract] [Full Text] [Related]

  • 17. Different selection patterns of resistance and cross-resistance to HIV-1 agents targeting CCR5.
    Armand-Ugón M, Moncunill G, Gonzalez E, Mena M, Ballana E, Clotet B, Esté JA.
    J Antimicrob Chemother; 2010 Mar 15; 65(3):417-24. PubMed ID: 20067983
    [Abstract] [Full Text] [Related]

  • 18. Design, synthesis, and biological evaluation of the combinatorial library with a new spirodiketopiperazine scaffold. Discovery of novel potent and selective low-molecular-weight CCR5 antagonists.
    Habashita H, Kokubo M, Hamano S, Hamanaka N, Toda M, Shibayama S, Tada H, Sagawa K, Fukushima D, Maeda K, Mitsuya H.
    J Med Chem; 2006 Jul 13; 49(14):4140-52. PubMed ID: 16821774
    [Abstract] [Full Text] [Related]

  • 19. Self-protection of individual CD4+ T cells against R5 HIV-1 infection by the synthesis of anti-viral CCR5 ligands.
    Guan Y, Abdelwahab S, Kamin-Lewis R, DeVico AL, Lewis GK.
    PLoS One; 2008 Jul 13; 3(10):e3481. PubMed ID: 18941536
    [Abstract] [Full Text] [Related]

  • 20. Effects of CC chemokine receptor 5 (CCR5) inhibitors on the dynamics of CCR5 and CC-chemokine-CCR5 interactions.
    Nakata H, Kruhlak M, Kamata W, Ogata-Aoki H, Li J, Maeda K, Ghosh AK, Mitsuya H.
    Antivir Ther; 2010 Jul 13; 15(3):321-31. PubMed ID: 20516552
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.